Winning investment in 2020

Blumorpho CEO Géraldine Andrieux discusses how start-ups should pitch for venture capital funding in uncertain economic times


t is hard to deny that Covid-19 has become one of the worst plagues

of the last 100 years. As well as health, it has had a drastic impact on the economy, with repercussions on investment capacities. If you are a technology start-up you might ask yourself how you can still get venture capital funding in this unprecedented crisis. Actually, one word could summarise the best approach to raising capital at the moment: adaptability. By adaptability, we do not

mean turning your company into a Covid-19-focused firm. Tat would be a very short- term strategy, not in line with investor expectations in terms of the bigger picture. By adaptability, we mean embracing the speed at which the economy is evolving as a result of the Covid-19 pandemic. Over the last seven to eight

months health systems, global logistics, education, working environments, production capacities and entire vertical businesses like aeronautics have been dramatically affected. At the same time, Covid-19 is accelerating digital transformation, change in human interactions and habits, as well as increasing awareness of climate change and its impact on our future. Covid-19 has shuffled the

cards and, more than ever, high-tech start-ups will have to adopt a bigger stance to raise capital. Let’s take the area of

healthcare as an example. Everybody agrees that when it comes to Covid-19 and its biomolecular mechanisms there are a lot of unknowns. Huge sums of public and private investment have been dedicated to supporting research to develop efficient therapies. Te Covid-19 crisis will

therefore generate new knowledge about biomolecular and cellular interactions. It will lead to a new era in biology and biotechnology to cure and treat Covid-19, but also push existing limits and contribute to the improvement of therapies in infectiology, as well as oncology, neuroscience, endocrinology and other fields. Any high-tech start-ups

addressing such challenges, while being on the edge of technologies including imaging, data mining, machine learning and computing that lead to accurate diagnoses, biomarkers and treatment, will find interest from private investors. Moreover, through Covid-19,

disease diagnostics and treatments are being made in large volumes and for fast delivery. Covid-19 not only has a huge impact on research,


‘To raise capital, high-tech companies have to demonstrate their value proposition with the right product market fit’

it generates fresh needs to accelerate clinical validation, and adapt production and delivery processes. It will generate new opportunities of growth and investment for companies supporting such evolutions, while building new models for optimising the existing processes.

It is also interesting to note

that the Covid-19 crisis came at a time when the world of investment, and many corporates, started focusing more on sustainable practices and those with a positive impact on society. Impact investment is becoming a key trend illustrated by the emergence of new funds. More traditional funds are also starting to adopt investment criteria in line with the United Nations’ Sustainable Development Goals. Impact investment should

not be considered another VC category focusing on social investment and not dealing with technology. Te investment thesis of deep tech private investors is evolving. High-tech start-ups will definitely have to consider such

@imveurope |

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44